DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNAPRNewsWire • 12/14/21
Digital Behavioral Health Innovator Ksana Health Joins Novo Nordisk's Global Prevention AcceleratorBusiness Wire • 12/09/21
Novo Nordisk announces impact from Volume Based Procurement for insulin in ChinaGlobeNewsWire • 11/26/21
Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker DicernaSeeking Alpha • 11/19/21
Novo Nordisk strikes $3.3 billion to buy research partner Dicerna PharmaceuticalsMarket Watch • 11/18/21
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021GlobeNewsWire • 11/08/21
Novo Nordisk A/S purchases B shares worth DKK 4,109 million from Novo Holdings A/S under the 2021 share repurchase programmeGlobeNewsWire • 11/05/21
Trading in Novo Nordisk shares by board members, executives and associated persons on 3 November 2021GlobeNewsWire • 11/04/21
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21